Loading…
Rekvina Labs (BSE 526075)₹67.06+9.88%Pharmaceuticals
In the Mar 2026 quarter (standalone), Rekvina Labs reported sales of ₹0.73 Cr and net profit of −₹0.05 Cr. For the year to Mar 2026, sales were ₹1.28 Cr and net profit −₹0.24 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Sep 2023 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.36 | 0.73 |
| Expenses | 0.00 | 0.06 | 0.01 | 0.03 | 0.03 | 0.22 | 0.46 | 0.77 |
| Operating Profit | −0.02 | −0.08 | −0.03 | −0.05 | −0.05 | −0.04 | −0.13 | −0.07 |
| OPM % | — | — | — | — | — | −15.0% | −34.3% | −8.3% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | −0.02 | −0.08 | −0.03 | −0.05 | −0.05 | −0.04 | −0.13 | −0.07 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Profit | 0.00 | −0.06 | −0.01 | −0.03 | −0.03 | −0.02 | −0.11 | −0.05 |
| EPS (Rs) | −0.02 | −0.07 | −0.03 | −0.04 | −0.04 | −0.03 | −0.11 | −0.06 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.04 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | −0.05 | 0.00 | 0.00 | 1.28 | 1.28 |
| Expenses | 0.02 | 0.11 | 0.04 | 0.09 | 0.14 | 0.05 | 0.03 | 0.01 | 0.13 | 1.51 | 1.48 |
| Operating Profit | 0.00 | −0.07 | −0.06 | −0.11 | −0.16 | −0.07 | −0.09 | −0.03 | −0.15 | −0.26 | −0.29 |
| OPM % | 0.0% | −99.9% | — | — | — | — | — | — | — | −19.6% | −22.7% |
| Other Income | 0.00 | 0.00 | 0.02 | 0.01 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | −0.07 | −0.03 | −0.09 | 0.00 | −0.07 | −0.09 | −0.03 | −0.15 | −0.26 | −0.29 |
| Tax % | — | 0.0% | 0.0% | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Net Profit | 0.00 | −0.05 | −0.01 | −0.07 | 0.00 | −0.05 | −0.07 | −0.01 | −0.13 | −0.24 | −0.21 |
| EPS (Rs) | 0.00 | −0.06 | −0.03 | −0.08 | 0.00 | −0.06 | −0.08 | −0.03 | −0.13 | −0.22 | −0.24 |
| Dividend payout % | — | 0.0% | 0.0% | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.02 | 3.02 | 3.02 | 3.02 | — | 3.02 | 3.02 | 3.02 | 3.02 | 3.02 | 3.02 | 3.02 |
| Reserves | −2.44 | −2.50 | −2.52 | −2.60 | — | −2.85 | −2.91 | −2.99 | −2.99 | −3.20 | −3.34 | −4.23 |
| Borrowings | 0.01 | 0.01 | 0.17 | 0.21 | — | 0.00 | 0.00 | 0.00 | 0.07 | 0.03 | 0.24 | 1.46 |
| Other Liabilities | 0.10 | 0.14 | 0.15 | 0.20 | — | 0.14 | 0.16 | 0.17 | 0.12 | 0.17 | 0.12 | 0.95 |
| Total Liabilities | 0.69 | 0.67 | 0.82 | 0.83 | — | 0.31 | 0.27 | 0.20 | 0.22 | 0.02 | 0.04 | 1.20 |
| Fixed Assets | 0.16 | 0.16 | 0.16 | 0.16 | — | 0.16 | 0.16 | 0.16 | 0.16 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.06 | 0.06 | 0.06 | 0.06 | — | 0.06 | 0.06 | 0.06 | 0.06 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.47 | 0.45 | 0.60 | 0.61 | — | 0.09 | 0.05 | −0.02 | 0.00 | 0.02 | 0.04 | 1.20 |
| Trade receivables | 0.24 | 0.27 | 0.24 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & equivalents | 0.00 | 0.02 | 0.12 | 0.14 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
| Total Assets | 0.69 | 0.67 | 0.82 | 0.83 | — | 0.31 | 0.27 | 0.20 | 0.22 | 0.02 | 0.04 | 1.20 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −0.03 | −0.05 | 0.02 | −0.03 | −0.02 | −0.02 | −0.05 | 0.02 | −0.02 | −0.20 | −0.60 |
| Cash from investing activity | 0.03 | 0.08 | −0.08 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from financing activity | 0.00 | 0.00 | 0.15 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.57 |
| Net cash flow | 0.00 | 0.02 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Free cash flow | −0.03 | −0.05 | 0.02 | −0.03 | −0.02 | −0.02 | −0.05 | 0.02 | −0.02 | −0.20 | −0.60 |
| CFO / OP % | — | 67.0% | −20.1% | 19.9% | 7.0% | 16.9% | 49.9% | — | 49.9% | 136.0% | 236.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 3,042 | 1,703 | — | — | — | 0 | — | 0 |
| Inventory days | — | — | — | — | — | 0 | — | 0 |
| Cash conversion cycle | 3,042 | 1,703 | — | — | — | 0 | — | 0 |
| Working capital days | 4,014 | 1,459 | — | — | — | −1,644 | — | −107 |
| ROCE % | 0.0% | −11.1% | −3.5% | −12.7% | −50.0% | −160.0% | 0.0% | −333.3% |
For the Mar 2026 quarter, Rekvina Labs reported sales of ₹0.73 Cr and net profit of −₹0.05 Cr. The operating margin was −8.3%.
Rekvina Labs' sales for the year to Mar 2026 were ₹1.28 Cr; over the last twelve months they were ₹1.28 Cr.
Net profit for the year to Mar 2026 was −₹0.24 Cr, and −₹0.21 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−0.24.
Rekvina Labs reported borrowings of ₹1.46 Cr at Mar 2026, against cash and equivalents of ₹0.01 Cr.
Cash from operations was −₹0.60 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹0.60 Cr.